In a special webinar from CancerNetwork®, Oncology Nursing News®, CURE®, and HCPLive®, a panel spanning multiple disciplines convened to speak about the use of GLP-1 receptor agonists (GLP-1 RAs) among patients undergoing treatment for breast cancer. The group covered whether GLP-1 RAs were safe for those with breast cancer and described the appropriate circumstances for care teams to consider them.
The panel was moderated by Neil M. Iyengar, MD, director of survivorship services at Winship Cancer Institute of Emory University, a clinical member of Winship’s Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor in chief of the journal ONCOLOGY®. He was joined by: